Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by WINTON GROUP Ltd

WINTON GROUP Ltd lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 70.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 313 shares of the biopharmaceutical company's stock after selling 755 shares during the quarter. WINTON GROUP Ltd's holdings in Regeneron Pharmaceuticals were worth $223,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock valued at $5,153,603,000 after buying an additional 61,277 shares during the period. Amundi boosted its holdings in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock valued at $1,138,074,000 after acquiring an additional 487,489 shares during the period. Charles Schwab Investment Management Inc. grew its position in Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company's stock valued at $495,639,000 after acquiring an additional 22,538 shares during the last quarter. TD Asset Management Inc. grew its position in Regeneron Pharmaceuticals by 8.9% in the 4th quarter. TD Asset Management Inc. now owns 359,389 shares of the biopharmaceutical company's stock valued at $256,004,000 after acquiring an additional 29,322 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its stake in Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company's stock worth $215,562,000 after purchasing an additional 1,108 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Remove Ads

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $8.60 during trading hours on Wednesday, hitting $625.60. 899,886 shares of the company's stock were exchanged, compared to its average volume of 679,610. The firm has a market cap of $68.39 billion, a P/E ratio of 16.34, a P/E/G ratio of 2.34 and a beta of 0.27. The firm has a 50 day moving average of $681.52 and a two-hundred day moving average of $788.06. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $603.47 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. During the same quarter in the previous year, the company earned $11.86 earnings per share. The company's quarterly revenue was up 10.3% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.56%. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on REGN. Canaccord Genuity Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. UBS Group lowered shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday, January 16th. BMO Capital Markets dropped their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $903.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 4th. Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price target for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Sanford C. Bernstein dropped their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $966.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.